Incyte (MEX:INCY) Total Operating Expense: MXN64,139 Mil (TTM As of Mar. 2026)


MEX:INCY Incyte Corp MEX:INCY
86 GF Score
Price MXN1,676.03
GF Value MXN1,443.22
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Total Operating Expense?

Incyte MEX:INCY 86 Total Operating Expense is MXN64,139 Mil as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 86/100 and a GF Value™ of MXN1,443.22 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Incyte's Total Operating Expense for the three months ended in Mar. 2026 was MXN15,220 Mil. Incyte's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN64,139 Mil.

Incyte Total Operating Expense Related Terms

Incyte Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Incyte's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Total Operating Expense Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45,843.83 50,611.79 47,278.39 79,831.93 61,693.87

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,609.18 15,551.36 15,329.96 18,037.61 15,219.65
MEX:INCY
86GF Score
Incyte Corp MEX:INCY
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN64,139 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of MXN64,139 Mil mean?
Incyte (MEX:INCY) has a Total Operating Expense of MXN64,139 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Incyte and its competitors.
Is Incyte's Total Operating Expense too high?
Incyte's current Total Operating Expense is MXN64,139 Mil. Overall, Incyte has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Total Operating Expense compare to INSM and BNTX?
Incyte's Total Operating Expense of MXN64,139 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Incyte and its competitors. Incyte's current Total Operating Expense is MXN64,139 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,443.22, compared to a current price of MXN1,676.03 — trading 16.1% above its estimated fair value. The current Total Operating Expense is MXN64,139 Mil. Incyte's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Total Operating Expense is MXN64,139 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 16.1% above its estimated GF Value™ of MXN1,443.22. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Total Operating Expense: MXN64,139 Mil
  • GF Value™: MXN1,443.22 vs. price of MXN1,676.03 (16.1% above fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
86GF Score

Get the complete analysis for MEX:INCY

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,443.22
GF Value